Merck sales disappoint as Januvia, Remicade fall short
(Reuters) - Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Diabetes | Endocrinology | Health | Januvia | Merck | Remicade | Rheumatology